<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-142334</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Review of the novelties from the 2014 ECTRIMS-ACTRIMS Joint Congress, presented at the 7th Post-ECTRIMS meeting (I)</dc:title>
<dc:description xml:lang="en">For the seventh year in a row the Post-ECTRIMS Meeting has been held in Madrid (Spain). Renowned specialists in multiple sclerosis and national leaders in this area have gathered once again to discuss the novelties presented at the 2014 ECTRIM-ACTRIMS World Congress. That meeting gave rise to this review, which will be published in two parts. One of the main conclusions in this first part is the deeper understanding of the genetic component of multiple sclerosis that we are acquiring, although it is still insufficient unless we bear in mind its interaction with the environmental risk factors of the disease or the impact of comorbidity and healthy habits on the patients&#146; susceptibility and prognosis. In this respect, the authors insist on the fact that, in clinical practice, the cognitive and psychiatric disorders remain under-diagnosed and are rarely taken into account in clinical research. Yet, although scarce, the evidence we have points to the possible benefits of disease-modifying drugs and alternatives to treatment with selective serotonin reuptake inhibitors. Addressing the subpopulations in multiple sclerosis and variants of the disease enhances the importance of an early accurate diagnosis in order to offer patients a safer and more personalised prognosis and treatment. Paediatric multiple sclerosis is ideal for studying the risk factors of the disease but, given its low prevalence, the use of prospective studies raises a number of doubts and there is a preference for conducting collaborative studies (AU)</dc:description>
<dc:creator>Álvarez Cermeño, José C</dc:creator>
<dc:creator>Meca Lallana, José E</dc:creator>
<dc:creator>Muñoz García, Delicias</dc:creator>
<dc:creator>Sainz, Albert</dc:creator>
<dc:creator>Ginestal, Ricardo</dc:creator>
<dc:creator>Fernández, Óscar</dc:creator>
<dc:creator>Brieva, Lluís</dc:creator>
<dc:creator>Ramió Torrenta, Lluís</dc:creator>
<dc:creator>Rodríguez AntigÜedad, Alfredo</dc:creator>
<dc:creator>Arroyo, Rafael</dc:creator>
<dc:creator>Montalban, Xavier</dc:creator>
<dc:creator>Romero Pinel, Lucía</dc:creator>
<dc:creator>Comabella, Manuel</dc:creator>
<dc:creator>Izquierdo, Guillermo</dc:creator>
<dc:creator>Oliva Nacarino, Pedro</dc:creator>
<dc:creator>Casanova Estruch, Bonaventrua</dc:creator>
<dc:creator>Olascoaga, Javier</dc:creator>
<dc:creator>García Merino, Juan A</dc:creator>
<dc:creator>Mendibe Bilbao, María del Mar</dc:creator>
<dc:creator>Calles Hernández, M. Carmen</dc:creator>
<dc:creator>Tintoré, Mar</dc:creator>
<dc:creator>Oreja Guevara, Celia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Por séptimo año consecutivo se ha celebrado en Madrid (España) la Reunión Post-ECTRIMS. Reconocidos especialistas en esclerosis múltiple y líderes de opinión nacionales se han reunido un año más para exponer las novedades presentadas en el Congreso Mundial ECTRIMS-ACTRIMS 2014, y fruto de esa reunión se genera esta revisión que sale publicada en dos partes. Como principales conclusiones de esta primera parte se destaca el mayor entendimiento del componente genético de la esclerosis múltiple al que estamos asistiendo, el cual no resulta suficiente si no se considera su interacción con los factores ambientales de riesgo de la enfermedad, ni el impacto de la comorbilidad y de las conductas saludables en la susceptibilidad y pronóstico de los pacientes. Al respecto, los autores insisten en que, en la práctica clínica, las alteraciones cognitivas y psiquiátricas están infradiagnosticadas y son poco consideradas en la investigación clínica; no obstante, la evidencia, aunque escasa, apunta hacia posibles beneficios de los fármacos modificadores de la enfermedad y alternativas al tratamiento inhibidor selectivo de la recaptación de serotonina. El abordaje de las subpoblaciones en esclerosis múltiple y variantes de la enfermedad refuerza la importancia del diagnóstico precoz y preciso para ofrecer a los pacientes un pronóstico y un tratamiento más seguros y personalizados. La esclerosis múltiple pediátrica es idónea para estudiar factores de riesgo de la enfermedad, pero dada su baja prevalencia, se cuestionan los estudios prospectivos y se aboga por los estudios colaborativos (AU)</dc:description>
<dc:source>Rev Neurol;61(5): 215-224, 1 sept., 2015. tab</dc:source>
<dc:identifier>ibc-142334</dc:identifier>
<dc:title xml:lang="es">Revisión de las novedades del congreso conjunto ECTRIMS-ACTRIMS 2014, presentadas en la VII Reunión Post-ECTRIMS (I)</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d3250</dc:subject>
<dc:subject>^d9951</dc:subject>
<dc:subject>^d9296^s22047</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d9296^s22027</dc:subject>
<dc:subject>^d3883</dc:subject>
<dc:subject>^d3103</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29594</dc:subject>
<dc:subject>^d3965</dc:subject>
<dc:subject>^d23661</dc:subject>
<dc:subject>^d29486</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d4736</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d1738</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d23925</dc:subject>
<dc:subject>^d28441^s22066</dc:subject>
<dc:subject>^d12940</dc:subject>
<dc:subject>^d15210</dc:subject>
<dc:subject>^d9296^s22033</dc:subject>
<dc:type>article</dc:type>
<dc:date>201509</dc:date>
</metadata>
</record>
</ibecs-document>
